Matches in SemOpenAlex for { <https://semopenalex.org/work/W4289878381> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W4289878381 endingPage "i3" @default.
- W4289878381 startingPage "i3" @default.
- W4289878381 abstract "Abstract Inhibitors of Bruton’s tyrosine kinase (BTK) are approved treatments for several B cell lymphomas. However, they are characterized by modest selectivity and/or limited central nervous system (CNS) exposure which is important in instances of CNS disease. GB5121 is an orally available, selective, irreversible, covalent small molecule BTK inhibitor that was designed to address these limitations. Here, GB5121 was profiled for selectivity, potency, inactivation kinetics and CNS penetrance in comparison to ibrutinib. GB5121 pharmacodynamic properties were evaluated using both cell-free enzymatic and cell-based functional assays, showing nM potency for BTK inhibition and rapid BTK inactivation kinetics (Kinact/Ki) in both peripheral and CNS tissue, a critical parameter for irreversible inhibitors. In a kinome scan, GB5121 exhibited high kinase selectivity against 349 kinases with only TEC/TXK demonstrating >50% inhibition at 1 µM; GB5121 did not inhibit phosphorylation of EGFR in a cell-based assay. When compared with other BTK inhibitors, GB5121 showed superior CNS target occupancy using a probe-based ELISA measuring free BTK in the brain of mice receiving 3 daily oral doses. GB5121 also demonstrated significantly higher brain to plasma ratio in mice with an intact blood brain barrier. In non-human primates, a 1:1 brain to plasma concentration ratio was demonstrated for GB5121 for up to 8 hours with both oral (30 mg/kg) and IV (2 mg/kg) doses. Together, these features differentiate GB5121 from both FDA-approved BTK inhibitors, as well as those currently under clinical investigation. Our data supports the use of GB5121 in clinical trials where BTK is a known driver of malignancies, including CNS lymphoma. This research has been previously presented at the AACR Annual Meeting 2022." @default.
- W4289878381 created "2022-08-05" @default.
- W4289878381 creator A5007369674 @default.
- W4289878381 creator A5012255396 @default.
- W4289878381 creator A5027382591 @default.
- W4289878381 creator A5035596475 @default.
- W4289878381 creator A5038297657 @default.
- W4289878381 creator A5039478407 @default.
- W4289878381 creator A5040898659 @default.
- W4289878381 creator A5046110842 @default.
- W4289878381 creator A5071899034 @default.
- W4289878381 creator A5088314635 @default.
- W4289878381 date "2022-08-01" @default.
- W4289878381 modified "2023-10-14" @default.
- W4289878381 title "BSCI-11 GB5121 IS A NOVEL, IRREVERSIBLE, COVALENT BTK INHIBITOR WITH HIGH SELECTIVITY AND CNS-PENETRANCE FOR TREATMENT OF CNS MALIGNANCIES" @default.
- W4289878381 doi "https://doi.org/10.1093/noajnl/vdac078.010" @default.
- W4289878381 hasPublicationYear "2022" @default.
- W4289878381 type Work @default.
- W4289878381 citedByCount "0" @default.
- W4289878381 crossrefType "journal-article" @default.
- W4289878381 hasAuthorship W4289878381A5007369674 @default.
- W4289878381 hasAuthorship W4289878381A5012255396 @default.
- W4289878381 hasAuthorship W4289878381A5027382591 @default.
- W4289878381 hasAuthorship W4289878381A5035596475 @default.
- W4289878381 hasAuthorship W4289878381A5038297657 @default.
- W4289878381 hasAuthorship W4289878381A5039478407 @default.
- W4289878381 hasAuthorship W4289878381A5040898659 @default.
- W4289878381 hasAuthorship W4289878381A5046110842 @default.
- W4289878381 hasAuthorship W4289878381A5071899034 @default.
- W4289878381 hasAuthorship W4289878381A5088314635 @default.
- W4289878381 hasBestOaLocation W42898783811 @default.
- W4289878381 hasConcept C185592680 @default.
- W4289878381 hasConcept C203014093 @default.
- W4289878381 hasConcept C2777938653 @default.
- W4289878381 hasConcept C2778461978 @default.
- W4289878381 hasConcept C2779878957 @default.
- W4289878381 hasConcept C42362537 @default.
- W4289878381 hasConcept C502942594 @default.
- W4289878381 hasConcept C55493867 @default.
- W4289878381 hasConcept C62478195 @default.
- W4289878381 hasConcept C71924100 @default.
- W4289878381 hasConcept C90059517 @default.
- W4289878381 hasConcept C98274493 @default.
- W4289878381 hasConceptScore W4289878381C185592680 @default.
- W4289878381 hasConceptScore W4289878381C203014093 @default.
- W4289878381 hasConceptScore W4289878381C2777938653 @default.
- W4289878381 hasConceptScore W4289878381C2778461978 @default.
- W4289878381 hasConceptScore W4289878381C2779878957 @default.
- W4289878381 hasConceptScore W4289878381C42362537 @default.
- W4289878381 hasConceptScore W4289878381C502942594 @default.
- W4289878381 hasConceptScore W4289878381C55493867 @default.
- W4289878381 hasConceptScore W4289878381C62478195 @default.
- W4289878381 hasConceptScore W4289878381C71924100 @default.
- W4289878381 hasConceptScore W4289878381C90059517 @default.
- W4289878381 hasConceptScore W4289878381C98274493 @default.
- W4289878381 hasIssue "Supplement_1" @default.
- W4289878381 hasLocation W42898783811 @default.
- W4289878381 hasOpenAccess W4289878381 @default.
- W4289878381 hasPrimaryLocation W42898783811 @default.
- W4289878381 hasRelatedWork W1780111622 @default.
- W4289878381 hasRelatedWork W1794509960 @default.
- W4289878381 hasRelatedWork W1830209188 @default.
- W4289878381 hasRelatedWork W2028681024 @default.
- W4289878381 hasRelatedWork W2154945466 @default.
- W4289878381 hasRelatedWork W2197292765 @default.
- W4289878381 hasRelatedWork W2529033697 @default.
- W4289878381 hasRelatedWork W2789446032 @default.
- W4289878381 hasRelatedWork W4378591451 @default.
- W4289878381 hasRelatedWork W4385971005 @default.
- W4289878381 hasVolume "4" @default.
- W4289878381 isParatext "false" @default.
- W4289878381 isRetracted "false" @default.
- W4289878381 workType "article" @default.